Diagnostic delay as main contributing factor to a large outbreak of tuberculosis in a university. / Demora diagnóstica como principal factor contribuyente a un importante brote de tuberculosis en una universidad.

OBJECTIVE: To describe the epidemiological characteristics of a large tuberculosis outbreak in the university environment and the main risk factors associated with it. METHOD: A descriptive analysis of the data collected from sick individuals and their contacts was made. For the contact tracing, the guidelines established in the Tuberculosis Programme of the Autonomous Community of the Basque Country were followed. Six of the outbreak strains were sent to the National Centre of Microbiology for molecular typing. RESULTS: The total number of cases of the outbreak was 11. The rate of tuberculosis infection in the classroom of the index case, including the sick individuals, was 88.1% (59 infected and only 8 uninfected). The diagnostic delay of the index case was 260 days, and in the other 8 symptomatic cases it ranged between 10 and 70 days. The pattern obtained by the 2genotyping techniques was identical in the 6 strains studied. CONCLUSIONS: The long diagnostic delay of the authentic index case, which was diagnosed in the contact tracing, and the poor ventilation conditions of the classroom, determined the high number of secondary cases associated with this outbreak.

[Inhaled colistin in elderly patients with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa bronchial infection]. / Tratamiento inhalado con colistina a largo plazo en pacientes ancianos con infección crónica por Pseudomonas aeruginosa y bronquiectasias.

BACKGROUND: Bronchiectasis is a frequent cause of admission for elderly patients and chronic respiratory diseases. Although some guidelines recommend long-term treatment with inhaled antibiotics in non-cystic fibrosis bronchiectasis with chronic Pseudomonas aeruginosa (P. aeruginosa) infection, there is limited evidence supporting these prolonged antibiotic treatments in this population. The aim of this study was to assess the effectiveness of inhaled colistin in elderly patients with bronchiectasis and chronic bronchial P. aeruginosa infection in reducing hospital readmissions. MATERIAL AND METHODS: A prospective, controlled and open label study was conducted on patients with bronchiectasis diagnosed by computed tomography and persistence of P. aeruginosa in sputum after appropriate antimicrobial therapy. All patients received education, and physiotherapy training. The intervention group also received nebulized colistin 1 million IU twice a day for one year. Data were collected on the demographics, clinical and functional characteristics, admissions in previous year, and sputum microbiology. Patients were followed up every two months for one year, with readmissions, microbiological results, functional tests, and deaths being evaluated. RESULTS: The study included 39 patients, of whom 20 received nebulized colistin and 19 conventional therapy. There were no differences between the two groups in baseline clinical and functional characteristics or previous hospital stay. The mean age was 77.7+/-5, Charlson index 2.85, and FEV1% 41.3+/-15. Five patients (25%) stopped the nebulized treatment because of adverse effects. P. aeruginosa was eradicated in 45% of the colistin treated patients, and in only one of the control group (statistically significant), but at the end of the study year, there were no differences in the number of hospital admissions (control group 1.6+/-1.7 and 2.7+/-3 colistin group), or days of stay (19+/-31 and 23+/-20). There were no differences in lung function or clinical symptoms between the two groups No significant changes were observed in P. aeruginosa A antibiotic sensitivity or in sputum flora. CONCLUSIONS: More patients in the treatment group achieved Pseudomonas eradication, but benefits in clinical symptoms, lung function or use of healthcare resources in our elderly patients, could not be demonstrated. Adverse effects were common. Further studies are needed in order to identify factors associated with response, or subgroups of patients with bronchiectasis and chronic infection with P. aeruginosa, who benefit from (expensive) long term treatments with inhaled antibiotics.